Endo Continues To Expand Generics Business With Par Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
After losing out on Salix to competitor Valeant, Endo makes a strong move into sterile injectables and other alternative dosage forms, and positions itself as the No. 5 generics firm in the U.S.